Healthcare / BiotechnologyNasdaqCM
$5.24
+0.33 (+6.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.8M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
-149.4%
↓Gross Margin
N/A
•Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.0M · FCF $-25.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | — | — | — | — | $3.1M | $12.3M | $4.3M | $32.4M | $23.1M | $14.7M | $10.0M | $33.6M |
| Net Income | $-26.0M | $-26.0M | $-24.1M | $-17.4M | $8.0M | $-28.5M | $-17.8M | $-40.4M | $-53.7M | $7.0M | $-112.4M | $-59.3M |
| EBITDA | $-26.1M | $-26.1M | $-24.3M | $-28.3M | $-27.7M | $-20.3M | $-26.1M | $-38.7M | $-49.3M | $-50.8M | $-135.4M | $-58.2M |
| EPS | -87.27 | -87.27 | -31460.23 | -527606.06 | 729727.27 | -3557505.60 | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | -919.7% | -174.1% | -638.1% | -126.3% | -224.0% | -368.1% | -1389.8% | -181.8% |
| Net Margin | — | — | — | — | 257.8% | -231.5% | -411.9% | -124.7% | -232.8% | 47.6% | -1125.8% | -176.5% |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.27 | 0.27 | 1.14 | 0.44 | 0.53 | 3.05 | 1.70 | — | 0.63 | 0.19 | 0.36 | — |
| Current Ratio | 3.36 | 3.36 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-25.6M | $-25.6M | $-23.8M | $-11.7M | $-21.1M | $-22.4M | $-29.4M | $-42.5M | $-52.4M | $-43.0M | — | — |
| Returns | ||||||||||||
| ROE | -149.4% | -149.4% | -507.5% | -142.5% | 44.7% | -2340.2% | -107.0% | -341.6% | -176.6% | 8.5% | -222.3% | -66.9% |
| Valuation | ||||||||||||
| P/E | 0.00 | 0.00 | — | — | 1.75 | — | — | — | — | — | — | — |
| P/B | 0.10 | 0.10 | 1.40 | 0.28 | 0.78 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | — | — | — | — | — | 185.3% | -86.7% | 40.6% | 57.4% | 46.8% | -70.3% | — |
| EPS Growth | 99.7% | 99.7% | 94.0% | -172.3% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-93.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-31460.23 → -87.27
Residual
-93.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.